Data originally collected every three months between October 2021 and April 2022 were extracted. Data were originally collected via questionnaires that were responded by proxy, such as facility managers, care managers, nurses, or other caregiving staff at nursing homes at 0 month, 3 months, and 6 months from October 2021(baseline).
The data source included demographics and clinical characteristics of participants, including age, sex, independence in activity of daily living owing to dementia assessed using the “Criteria for determination of the daily life independence level of the elderly with dementia” [19 ], prescribed anti-dementia drugs (i.e., donepezil, galantamine, rivastigmine, memantine, and yokukansan/YiganSan), activities of daily living (ADL) assessed using Barthel Index (BI) [20 ], occupation/position of the proxies who responded to the EQ-5D-5L+C and EQ-5D-5L [2, 6, 14– 17 (link)], EQ-5D-5L+C (proxy version responded by proxy), EQ-5D-5L (proxy version responded by proxy), and MMSE [18 (link)].
The data source included demographics and clinical characteristics of participants, including age, sex, independence in activity of daily living owing to dementia assessed using the “Criteria for determination of the daily life independence level of the elderly with dementia” [19 ], prescribed anti-dementia drugs (i.e., donepezil, galantamine, rivastigmine, memantine, and yokukansan/YiganSan), activities of daily living (ADL) assessed using Barthel Index (BI) [20 ], occupation/position of the proxies who responded to the EQ-5D-5L+C and EQ-5D-5L [2, 6, 14– 17 (link)], EQ-5D-5L+C (proxy version responded by proxy), EQ-5D-5L (proxy version responded by proxy), and MMSE [18 (link)].
Free full text: Click here
